BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» CGT-4255, a novel ErbB2 inhibitor with antitumor efficacy in ErbB2-mutant models
To read the full story,
subscribe
or
sign in
.
Cancer
CGT-4255, a novel ErbB2 inhibitor with antitumor efficacy in ErbB2-mutant models
Dec. 20, 2023
No Comments
Researchers from Cogent Biosciences Inc. have reported the discovery and preclinical characterization of CGT-4255, a novel EGFR-sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutations.
BioWorld Science
Conferences
New compound
Cancer
